多灶性运动神经病
Multifocal motor neuropathy
定义 英文原文(暂无中文)
Multifocal motor neuropathy (MMN) is a rare acquired immune-mediatedneuropathy characterized clinically by a purely motor deficit with conduction block and asymmetric multifocal weakness, fasciculations, and cramping.
别名
多灶性运动神经病伴传导阻滞
基本事实
- 遗传方式
- 未知
- 发病年龄
- 成年期
- 患病率
- 1-9 / 100 000
临床表型 12
极常见 99–80%1
- 进行性远端肌无力 HP:0009063
常见 79–30%11
- 神经节苷脂代谢异常 HP:0004345
- 肌束震颤 HP:0002380
- 功能性运动障碍 HP:0004302
- 脑脊液蛋白浓度增加 HP:0002922
- 四肢肌肉无力 HP:0003690
- 伸腕受限 HP:0006251
- 运动传导阻滞 HP:0012078
- 肌肉痉挛 HP:0003394
- 进行性肌无力 HP:0003323
- 腱反射减低 HP:0001315
- 第三指伸肌无力 HP:0009077
近两年的全球研究 279L2
2024/10 起在 Europe PMC 检索所得,按发表时间倒序显示最近 20 篇。标题未译成中文——自动翻译需要接入 LLM 服务,尚未引入。
- 2026-09The role of leukocyte p38 MAP kinase in immune-mediated peripheral polyneuropathies: distinct modulation by intravenous immunoglobulins
- 2026-09综述开放获取Neurovascular Unit Dysfunction and Neural Barrier Pathology in Dysautonomia: Molecular Links to Cardiovascular Autonomic Failure
- 2026-09系统综述开放获取Comparative efficacy, safety, and functional recovery of neonatal fc receptor inhibitors and conventional immunotherapies for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review and network meta-analysis
- 2026-09Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach From the Writing Committee of the American Society for Apheresis: The Tenth Special Issue
- 2026-09开放获取High Resolution 3-T Magnetic Resonance Tractography Cannot Localise Conduction Block in Multifocal Motor Neuropathy With Conduction Block
- 2026-09开放获取Unexpected Conduction Blocks in <i>SORD</i>-Related Distal Motor Neuropathy: A Case Report
- 2026-09Spectrum of Hereditary Neuropathies in Adult Patients From Serbia
- 2026-08荟萃分析系统综述开放获取Effects of therapeutic plasma exchange (TPE) on efficacy and adverse events in patients with autoimmune neurological diseases: a systematic review and meta-analysis based on real-world studies and single-arm clinical trials
- 2026-08综述开放获取Magnetic resonance imaging applications to amyotrophic lateral sclerosis beyond the central nervous system
- 2026-08综述开放获取A cardiovascular-motor axis framework for perfusion-mediated motor impairment
- 2026-08Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% as Maintenance Therapy for Japanese Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Multifocal Motor Neuropathy: A Phase 3, Open-label Clinical Trial
- 2026-08综述开放获取Diffusion-Weighted Imaging in the Musculoskeletal System: Evolving Role in Modern Imaging Practice
- 2026-08病例报告开放获取An Unusual Iatrogenic Complication of Botulinum Toxin: Forearm Flexor Weakness Following a Nonstandard Intradermal Sensitivity Test
- 2026-08综述开放获取The Role of Neurofilaments in Diagnosis and Monitoring of Amyotrophic Lateral Sclerosis
- 2026-08病例报告开放获取Ganglioside Antibodies as Formidable Neurologic Mimickers: A Case Report of Dual Anti-GQ1b and Asialo-GM1 Antibody Syndrome
- 2026-08病例报告开放获取Bilateral Parsonage-Turner Syndrome in a Young Adult Man Due to Parvovirus B19 Infection
- 2026-08开放获取Neuralgic amyotrophy - Beyond the plexus: A case of surgical treatment of bilateral distal peripheral nerve involvement in neuralgic amyotrophy/Parsonage-Turner Syndrome
- 2026-08病例报告开放获取Cladribine treatment in chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy: two case reports
- 2026-08综述开放获取MyD88-Family Adaptors: Compartmentalised Signalling and Non-Immune Functions
- 2026-08开放获取Refining Electrophysiological Criteria in CIDP and MMN: Toward a Unified Definition of Motor Conduction Block and Proximal Temporal Dispersion
境外已获批用于本病的药物 1L2
欧盟 0 项、美国 1 项。同一药物在两地各批一次的,会分别列出。
「境外已获批」不等于「在中国能用」。中间隔着进口注册、临床急需境外新药通道、海南博鳌乐城国际医疗旅游先行区等几条路径,各有各的条件与费用。这一节能确定地告诉你的只有一件事:这个病在世界范围内已经有获得批准的药物,它叫什么名字。拿这个名字去问主治医生,是下一步最省力的做法。
药名一律保留英文原文,不作翻译——中国的药品通用名与英文名的音译经常不一致,译错会让人去找一个不存在的药。
- Gammagard Liquid美国2012-06-22immune globulin infusion (human)官方记录
尚未获批的在研药物(2 项)
这些药已被欧盟或美国的监管机构认定为罕见病用药(英文 orphan drug designation,中文行业里通称「孤儿药资格」——「孤儿」说的是这类药市场太小、没有厂商愿意认领,不是在说病人)。但这只是一种监管身份:意味着监管机构给予研发上的激励,不代表这个药已被证明有效,也不代表将来一定能上市,绝大多数最终不会成药。列在这里是为了看清有哪些方向正在被尝试。
数据来自欧洲药品管理局(EMA)的药品与罕见病用药资格公开导出表,以及美国 FDA 的罕见病用药资格数据库(Orphan Drug Product Designation Database)。两边口径不同:欧盟一侧取的是当前状态仍为「已授权」的药品;美国一侧记录的是「曾获批准」这一事实,FDA 的公开表不追踪药物此后是否退市(例如 Relyvrio 于 2024 年撤市,表中仍记为已获批)。请以官方记录页为准。
在中国开展的临床试验 3L2
按病名在 ClinicalTrials.gov 检索、并校验研究中心含中国大陆而来。登记状态不等于现在真的能入组——务必按 NCT 号到原站核实,并与主治医生商量。
当前没有检索到登记为可入组的试验。
其他状态的试验(3 项)
- 进行中·不再招募NCT05988073A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy中国研究中心 3 个:Changsha、Nanchang、Shanghai
- 进行中·不再招募NCT06537999A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy中国研究中心 3 个:Beijing、Shanghai
- 进行中·不再招募NCT06742190A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy中国研究中心 1 个:Shanghai
中国境外的在招试验 2L2
这些试验在中国没有研究中心,通常无法直接报名——入组一般要求在当地居住并接受随访。列在这里是因为它另有用处:看清楚全世界正在试哪些药、做到了哪一期、由谁在做。把药名和 NCT 编号记下来去问主治医生,或据此进一步查该药是否已在境外获批、是否有拓展性用药(expanded access)通道。
共 2 项。
- 招募中NCT07610564A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor NeuropathyGeorgia
- 招募中NCT01793168Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford澳大利亚、美国
外部标识与链接
发现这一页有错误?告诉我 · 邮件主题会自动带上本页的 ORPHA 编号
本页数据来源
- 疾病定义、同义词、基因、表型、流行病学:Orphanet(CC BY 4.0)
- 中文病名:Orphanet 中文包,冻结于 2020-06-01
- 表型中文标签:HPO 简体中文翻译(CHPO 上游成果)